After losing the top spot in March to Johnson & Johnson’s immunology drug Tremfya, AbbVie’s rival med Skyrizi is back as the ...
Zumilokibart advancing across multiple indications, with Phase 3 initiation in atopic dermatitis (AD) expected later this year:- APEX Phase 2 ...
Nektar is positioning REZPEG as a differentiated 'upstream' immune modulator that restores balance rather than simply ...
Regeneron Pharmaceuticals, Inc. ( REGN) Bank of America Global Healthcare Conference 2026 May 12, 2026 1:00 PM EDT ...
Diana Taurasi knows a thing or two about playing under pressure, from facing down crowds in Tennessee and Turkey to the ...
Audio Gap] chatting with Kymera Therapeutics. Up here on stage, we've got a couple of members from the management team. We've got Bruce Jacobs, who's, of course, is Chief Financial Officer; as well as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results